Vitiligo Market Growth to Undergo Significant Changes by 2032, Predicts DelveInsight | Key Companies in the Market – Clinuvel Pharmaceuticals Limited, Pfizer, Incyte Corporation, Amgen

The available therapeutics treatment options in the vitiligo market landscape aim to reduce complications arising. The dynamics of the vitiligo market are anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world.

LAS VEGAS, Nov. 7, 2023 /PRNewswire/ — DelveInsight’s Vitiligo Market Insights report includes a comprehensive understanding of current treatment practices, vitiligo emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Vitiligo Market Report

• As per DelveInsight analysis, the vitiligo market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• As Per DelveInsight’s estimates, the 12 month prevalence of vitiligo in the 7MM was assessed to be 8.1 million in 2021,which is expected to increase during the study period (2019–2032).
• Globally, leading vitiligo companies such as Incyte Corporation, Amgen, Boston Pharmaceuticals, Arcutis Biotherapeutics, Pfizer, Dermavant Sciences, Clinuvel Pharmaceuticals, Celgene, TWi Biotechnology, AXIM Biotechnologies, Arrien Pharmaceuticals, and others are developing novel Vitiligo drugs that can be available in the Vitiligo market in the coming years.
• Some key therapies for vitiligo treatment include Afamelanotide, Crisaborole 2% Topical Ointment, Ruxolitinib 1.5% cream, Ritlecitinib, AMG 714, and others.

Discover which therapies are expected to grab the major vitiligo market share @ Vitiligo Market Report

Vitiligo Overview

Vitiligo is a frequently occurring skin condition characterized by well-defined white patches resulting from the loss of melanocytes in the epidermis. It is often linked to autoimmune disorders, with thyroid issues being the most common. While the precise cause of vitiligo remains unknown, genetic factors, autoimmunity, neurological influences, toxic metabolites, and a deficiency in melanocyte growth factors may be involved. This condition can manifest at any age, with the highest incidence occurring in the second and third decades of life. The age of onset varies between genders. Vitiligo affects people of all ethnic backgrounds, with a global prevalence ranging from 0.1% to 2%. Diagnosis primarily relies on clinical features, but a biopsy, especially when conducted under a wood light examination, can aid in distinguishing vitiligo from other conditions causing skin depigmentation.

Vitiligo Epidemiology Segmentation

The vitiligo epidemiology section provides insights into the historical and current vitiligo patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The vitiligo market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Twelve Month Prevalent Pool of Vitiligo
• Diagnosed Cases of Vitiligo
• Type-specific Diagnosed Cases of Vitiligo
• Treatable Cases of Vitiligo 

Vitiligo Treatment Market 

While there is no known cure, most vitiligo treatments are prescribed off-label. The primary goal of medical interventions is to achieve a uniform skin tone, either by restoring color (repigmentation) or removing remaining pigmentation (depigmentation). This condition is more commonly seen in individuals with autoimmune diseases and may have a familial component. Typically, it appears before the age of 40. Managing vitiligo involves options such as oral and topical prescription medications, light therapy, surgical procedures, and certain lifestyle modifications. Monobenzone, once the only FDA-approved vitiligo treatment, is no longer available on the vitiligo treatment market. July 2022 marked the momentous approval by the US FDA for topical OPZELURA (ruxolitinib) 1.5%, designed for the treatment of non-segmental vitiligo in patients aged 12 and above. This cream is an oil-in-water, solubilized emulsion with a white to off-white appearance, and a maximum weekly dose of 60 grams. European Union approval is expected soon.

Primary treatments for individuals with vitiligo typically involve the initial use of topical or oral prescription medications, either separately or in combination. Should these prove ineffective, medical professionals might recommend various alternative approaches, including repigmentation surgery, depigmentation treatments, or micropigmentation procedures. Steroid creams or ointments can be applied to the affected skin regions to modify the behavior of immune cells and combat inflammation, potentially preventing excessive tissue damage.

To know more about vitiligo treatment, visit @ Vitiligo Treatment Drugs 

Key Vitiligo Therapies and Companies

• Afamelanotide: Clinuvel Pharmaceuticals Limited
• Crisaborole 2% Topical Ointment: Pfizer
• Ruxolitinib 1.5% cream: Incyte Corporation
• Ritlecitinib: Pfizer
• AMG 714: Amgen

Learn more about the FDA-approved drugs for vitiligo @ Drugs for Vitiligo Treatment 

Vitiligo Market Dynamics

The vitiligo market dynamics of vitiligo have been evolving over the years. Several key factors influence this market. Firstly, increased awareness about vitiligo, driven by advocacy groups and public figures who openly discuss their experiences with the condition, has expanded the patient pool. This, in turn, has led to a growing demand for treatment options, including cosmetic camouflage products, topical corticosteroids, and surgical procedures.

Secondly, research and development efforts in the pharmaceutical and cosmetic industries have spurred innovation. New therapies, such as targeted biologics and melanocyte transplantation techniques, have emerged as promising treatments, adding dynamism to the market. Additionally, the influence of social media and the desire for inclusive beauty standards have fostered a demand for products that cater to individuals with vitiligo. The cosmetics industry, in particular, has recognized the need for more diverse product lines, further shaping the market dynamics.

However, several factors are impeding the growth of the vitiligo market. One significant barrier is the limited number of FDA-approved treatments specifically designed for vitiligo. Many of the existing therapies are repurposed from other conditions and may not be highly effective for all patients. Healthcare disparities can impede access to quality care for individuals with vitiligo, particularly for those without adequate insurance coverage or in regions with limited healthcare infrastructure. This lack of access can limit the vitiligo market’s growth potential.

Moreover, developing new treatments and therapies for vitiligo can be costly, and pharmaceutical companies may be hesitant to invest in research and development for what is considered a rare condition compared to other dermatological issues. Furthermore, the regulatory approval process for new vitiligo treatments can be lengthy and arduous, delaying their entry into the vitiligo market. This can be a barrier to innovation.

Scope of the Vitiligo Market Report

• Vitiligo Therapeutic Assessment: Vitiligo current marketed and emerging therapies
• Vitiligo Market Dynamics: Conjoint Analysis of Emerging Vitiligo Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Vitiligo Market Access and Reimbursement

Discover more about vitiligo drugs in development @ Vitiligo Clinical Trials

Table of Contents

Related Reports

Vitiligo Pipeline

Vitiligo Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key vitiligo companies, including Incyte Corporation, Amgen, Boston Pharmaceuticals, Arcutis Biotherapeutics, Pfizer, Dermavant Sciences, Clinuvel Pharmaceuticals, Celgene, TWi Biotechnology, AXIM Biotechnologies, Arrien Pharmaceuticals, among others.

Vitiligo Epidemiology

Vitiligo Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted vitiligo epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Psoriasis Pipeline

Psoriasis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriasis companies, including Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, among others.

Plaque Psoriasis Market

Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key plaque psoriasis companies including Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

[email protected]

+1(919)321-6187
www.delveinsight.com 

Logo – https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg 

SOURCE DelveInsight Business Research, LLP

Go to Source